The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
Here's a roundup of top developments in the biotech space over the last 24 hours:
Sana Biotechnology Obtains Exclusive License From National Institutes Of Health For CD22 CAR Construct
License will enable Sana's in vivo and ex vivo engineered T cell programs for B cell malignancies
Technology expected to help address key relapse challenges for
CD19-directed CAR T cell
Stocks Hitting New 52-Week Lows Today
On Monday morning, 60 companies achieved new lows for the year.
Sana Biotechnology Q3 EPS $(0.46) Up From $(3.76) YoY
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.46) per share. This is a 87.77 percent increase over losses of $(3.76) per share from the same period last year.
Sana Obtains License To Beam Therapeutics’ CRISPR Cas12b Gene Editing Technology
Sana Biotechnology Inc (NASDAQ:SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc’s (NASDAQ:BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy…
Goldman Sachs Maintains Neutral on Sana Biotechnology, Lowers Price Target to $34
Goldman Sachs maintains Sana Biotechnology (NASDAQ:SANA) with a Neutral and lowers the price target from $39 to $34.
Sana Biotechnology Q2 EPS $0.32; Cash Position Of $930.8M
Sana Biotechnology (NASDAQ:SANA) reported quarterly earnings of $0.32 per share.
Sana Biotechnology Q2 EPS $0.32
Sana Biotechnology (NASDAQ:SANA) reported quarterly earnings of $0.32 per share.